New combo therapy shows promise for tough-to-treat nose and throat cancer
NCT ID NCT05563480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug combination (TQB2618 plus penpulimab) in 47 people with advanced nasopharyngeal carcinoma that had come back or spread. Some participants had already tried standard treatments, while others were new to therapy. The goal was to see if the combination was safe and could shrink tumors or slow cancer growth. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530012, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510100, China
-
The Fifth Affiliated Hospital Sun Yat sen University
Zhuhai, Guangdong, 519000, China
-
Union Hospital Tongji Medical College, Huazhong University Of Science And Technology
Wuhan, Hubei, 430022, China
-
Xiangya Hospital Central South University
Changsha, Hunan, 410078, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers